Establishment of the model for selection of dominant advanced triple negative breast cancer patients with chemotherapy under the guidance of individualized gene detection

LIU Danna; WU Tong; CHEN Lu; DUAN Fangfang; ZHOU Hanli; KONG Tiandong

doi:10.7619/jcmp.20210332

Journal of Clinical Medicine in Practice > 2021 > 25(8): 11-15. > DOI: 10.7619/jcmp.20210332

LIU Danna, WU Tong, CHEN Lu, DUAN Fangfang, ZHOU Hanli, KONG Tiandong. Establishment of the model for selection of dominant advanced triple negative breast cancer patients with chemotherapy under the guidance of individualized gene detection[J]. Journal of Clinical Medicine in Practice, 2021, 25(8): 11-15. DOI: 10.7619/jcmp.20210332

Citation:

PDF (1260 KB)

Establishment of the model for selection of dominant advanced triple negative breast cancer patients with chemotherapy under the guidance of individualized gene detection

1.
Center for Drug Clinical Trials, Cancer Hospital of Henan University, The Third People's Hospital of Zhengzhou City of Henan Province, Zhengzhou, Henan, 450000
2.
School of Mathematics and Statistics of Henan University, Kaifeng, Henan, 475000
3.
Department of Oncology, Cancer Hospital of Henan University, The Third People's Hospital of Zhengzhou City of Henan Province, Zhengzhou, Henan, 450000

More Information

Received Date: January 17, 2021
Available Online: April 21, 2021
Published Date: April 27, 2021

Graphical Abstract

Abstract

Abstract

Objective To establish a model for therapeutic prediction of advanced triple negative breast cancer (TNBC) patients with chemotherapy under the guidance of individualized gene detection.
Methods Training set included 97 patients from May 2013 to May 2015 in Breast Center of Cancer Hospital of Henan University, they all participated in a clinical study on "Efficacy of advanced TNBC patients with chemotherapy based on the guidance of individualized gene detection". All the patients were conducted with chemotherapy, and the expressions of ERCC1, TOP2A, TUBB3 and TYMS genes were detected. Based on this group of people, the efficacy prediction model was established and verified internally. Logistic method was used to screen the efficacy-related predictive factors, and the predictive equation model and Nomogram were established finally.
Results Univariate analysis showed that histological grade, brain metastasis, Ki-67 index, score of Performance Status (PS), and expressions of ERCC1, TOP2A, TUBB3 and TYMS genes were correlated with efficacy (P < 0.05 or P < 0.01). Multivariate regression analysis showed that histological grade, brain metastasis, and the expressions of ERCC1, TOP2A and TUBB3 genes were correlated with efficacy (P < 0.05 or P < 0.01). Based on the results of multivariate regression, the efficacy prediction model was established and the Nomogram was drawn. The area under curve (AUC) of the model was 0.861, 95% CI was 0.789 to 0.933, and the best cut-off value was 0.739. Chi-square goodness-of-fit test showed no significant difference between predicted probability and measured probability (χ²=1.698, P=0.975).
Conclusion The model established in this study can predict the dominant advanced TNBC patients with chemotherapy and provide references for clinical decision-making.
- triple negative breast cancer,
- gene detection,
- chemotherapy efficacy,
- prediction model,
- Nomogram

FullText(HTML)

References (24)

References

[1]	KWA M J, ADAMS S. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here[J]. Cancer, 2018, 124(10): 2086-2103. doi: 10.1002/cncr.31272
[2]	郑红梅, 李祥, 金立亭, 等. 三阴性乳腺癌基因学分子分型和个体化治疗新进展[J]. 中华肿瘤防治杂志, 2016, 23(17): 1198-1204. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201617022.htm
[3]	WEIN L, LOI S. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC)[J]. Breast, 2017, 34(Suppl 1): S27-S30. http://www.sciencedirect.com/science/article/pii/S0960977617304952
[4]	PARK J H, AHN J H, KIM S B. How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies[J]. ESMO Open, 2018, 3(Suppl 1): e000357. http://esmoopen.bmj.com/content/3/Suppl_1/e000357.full
[5]	NAVRÁTIL J, FABIAN P, PALÁCOVÁ M, et al. Triple negativní karcinom prsu[Triple Negative Breast Cancer] [J]. Klin Onkol, 2015, 28(6): 405-415.
[6]	SHARMA P. Biology and management of patients with triple-negative breast cancer[J]. Oncologist, 2016, 21(9): 1050-1062. doi: 10.1634/theoncologist.2016-0067
[7]	SHACHAR S S, JOLLY T A, JONES E, et al. Management of triple-negative breast cancer in older patients: how is it different[J]. Oncol Williston Park N Y, 2018, 32(2): 58-63. https://pubmed.ncbi.nlm.nih.gov/29492945/
[8]	CAMORANI S, FEDELE M, ZANNETTI A, et al. TNBC challenge: oligonucleotide aptamers for new imaging and therapy modalities[J]. Pharmaceuticals (Basel), 2018, 11(4): E123-E133. doi: 10.3390/ph11040123
[9]	孔天东, 段方方, 王留晏, 等. 晚期三阴性乳腺癌TUBB3基因表达及与化疗疗效间关系[J]. 肿瘤学杂志, 2018, 24(3): 195-198. https://www.cnki.com.cn/Article/CJFDTOTAL-XHON201803003.htm
[10]	付朝红, 刘丹娜, 段方方, 等. 晚期三阴性乳腺癌核苷酸切除修复交叉互补基因1表达与化学治疗效果的关系[J]. 新乡医学院学报, 2017, 34(10): 904-907. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYX201710011.htm
[11]	孔天东, 刘丹娜, 刘萌萌, 等. 晚期三阴性乳腺癌TYMS基因表达及与化疗疗效相关研究[J]. 西部医学, 2019, 31(1): 43-46, 50. https://www.cnki.com.cn/Article/CJFDTOTAL-XIBU201901012.htm
[12]	刘丹娜, 孔天东, 张二峰, 等. TOP2A基因表达与三阴性乳腺癌化疗疗效的关系研究[J]. 医药论坛杂志, 2016, 37(10): 7-10. https://www.cnki.com.cn/Article/CJFDTOTAL-HYYX201610003.htm
[13]	KHOKHER S, QURESHI M U, CHAUDHRY N A. Comparison of WHO and RECIST criteria for evaluation of clinical response to chemotherapy in patients with advanced breast cancer[J]. Asian Pac J Cancer Prev, 2012, 13(7): 3213-3218. doi: 10.7314/APJCP.2012.13.7.3213
[14]	KUMAR P, AGGARWAL R. An overview of triple-negative breast cancer[J]. Arch Gynecol Obstet, 2016, 293(2): 247-269. doi: 10.1007/s00404-015-3859-y
[15]	MAROTTI J D, DE ABREU F B, WELLS W A, et al. Triple-negative breast cancer: next-generation sequencing for target identification[J]. Am J Pathol, 2017, 187(10): 2133-2138. doi: 10.1016/j.ajpath.2017.05.018
[16]	吴晓龙, 张奇, 张伟, 等. 晚期三阴性乳腺癌研究进展[J]. 国际老年医学杂志, 2020, 41(3): 197-201. https://www.cnki.com.cn/Article/CJFDTOTAL-GWLL202003019.htm
[17]	KIM C, GAO R, SEI E, et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing[J]. Cell, 2018, 173(4): 879-893. doi: 10.1016/j.cell.2018.03.041
[18]	ISAKOFF S J, MAYER E L, HE L, et al. TBCRC009: a multicenter phase Ⅱ clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer[J]. J Clin Oncol, 2015, 33(17): 1902-1909. doi: 10.1200/JCO.2014.57.6660
[19]	ALI A M, ANSARI J A K, EL-AZIZ N M A, et al. Triple negative breast cancer: a tale of two decades[J]. Anticancer Agents Med Chem, 2017, 17(4): 491-499. https://pubmed.ncbi.nlm.nih.gov/27456662/
[20]	SCHNEEWEISS A, DENKERT C, FASCHING P A, et al. Diagnosis and therapy of triple-negative breast cancer (TNBC)-recommendations for daily routine practice[J]. Geburtshilfe Frauenheilkd, 2019, 79(6): 605-617. doi: 10.1055/a-0977-4248
[21]	BAO B, PRASAD A S. Targeting CSC in a most aggressive subtype of breast cancer TNBC[J]. Adv Exp Med Biol, 2019, 1152: 311-334. http://www.researchgate.net/publication/335441423_Targeting_CSC_in_a_Most_Aggressive_Subtype_of_Breast_Cancer_TNBC
[22]	LÓPEZ-OZUNA V M, HACHIM I Y, HACHIM M Y, et al. Prolactin modulates TNBC aggressive phenotype limiting tumorigenesis[J]. Endocr Relat Cancer, 2019, 26(3): 321-337. http://www.researchgate.net/publication/330377613_Prolactin_modulates_TNBC_aggressive_phenotype_limiting_tumorigenesis
[23]	NARRANDES S, HUANG S J, MURPHY L, et al. The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC)[J]. BMC Cancer, 2018, 18(1): 22-31. doi: 10.1186/s12885-017-3939-4
[24]	SHI Y Q, JIN J, WANG X, et al. DAXX, as a tumor suppressor, impacts DNA damage repair and sensitizes BRCA-proficient TNBC cells to PARP inhibitors[J]. Neoplasia, 2019, 21(6): 533-544. http://www.ncbi.nlm.nih.gov/pubmed/31029033

[1]	SHI Qianqian, LIU Jingjing. Risk factor and construction of nomogram prediction model for pertussis in children[J]. Journal of Clinical Medicine in Practice, 2025, 29(6): 56-61. DOI: 10.7619/jcmp.20244333
[2]	WANG Wang, ZHAO Han. Construction of a nomogram prediction model for catheter-related bloodstream infections in hemodialysis patients with chronic renal failure[J]. Journal of Clinical Medicine in Practice, 2024, 28(18): 95-100. DOI: 10.7619/jcmp.20240464
[3]	ZHU Huayuan, ZHANG Yajuan, SUN Qian, HUANG Yan, YANG Bingyin. Establishment of a Nomogram prediction model for chronic constipation patients based on body position exercise training[J]. Journal of Clinical Medicine in Practice, 2024, 28(17): 109-113. DOI: 10.7619/jcmp.20241488
[4]	CHEN Chunmei, ZHANG Rong, CHU Jie, WANG Xuexing. Influencing factors of malnutrition in patients with colorectal cancer and value of Nomogram prediction model[J]. Journal of Clinical Medicine in Practice, 2024, 28(17): 20-26. DOI: 10.7619/jcmp.20241893
[5]	REN Weiwei, WANG Chao, MENG Junhua, XU Suhong. Establishment and validation of an individualized risk prediction nomogram model for gestational diabetes mellitus in pregnant women with hypothyroidism[J]. Journal of Clinical Medicine in Practice, 2024, 28(16): 93-97. DOI: 10.7619/jcmp.20234265
[6]	WU Xueqin, JIN Rong, CAO Xia. Construction of nomogram model for predicting risk of maternal postpartum chronic low back pain[J]. Journal of Clinical Medicine in Practice, 2023, 27(16): 121-126. DOI: 10.7619/jcmp.20231835
[7]	ZHU Ting, ZHOU Hailan, HUA Xiaofan. Establishment and application of Nomogram model for prediction of recurrence after breast cancer surgery based on multi-dimensional indicators[J]. Journal of Clinical Medicine in Practice, 2023, 27(5): 43-48. DOI: 10.7619/jcmp.20221838
[8]	DONG Yanping, WANG Jiemin, WANG Yujin, REN Yali, DONG Yucheng, YONG Yanjun, SU Xuandi, WANG Jixiang, SU Nan, WANG Fuli, XIA Duosheng. Construction and evaluation of Nomogram prediction model for postoperative recurrence of pterygium[J]. Journal of Clinical Medicine in Practice, 2022, 26(7): 52-56. DOI: 10.7619/jcmp.20214610
[9]	HU Tingting, GUO Qiu, TANG Weiwei, YANG Huan, LIU Guijun. A Nomogram model establishment for noscomial infection in elderly patients with hypertension and diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2021, 25(5): 55-60. DOI: 10.7619/jcmp.20210055
[10]	ZHANG Zhen, ZHANG Hengzhu, LI Yuping, YAN Zhengcun, DONG Lun, WANG Xiaodong, WANG Xingdong. Relationship between systemic inflammation response index and symptomatic cerebral vasospasm after aneurismal subarachnoid hemorrhage as well as construction of a Nomogram predictive model[J]. Journal of Clinical Medicine in Practice, 2020, 24(10): 36-40. DOI: 10.7619/jcmp.202010009

Cited By

Cited by

Periodical cited type(10)

1.	徐颖. 多层螺旋CT联合核磁共振成像增强扫描在胰腺癌及慢性胰腺炎鉴别诊断中的价值分析. 大医生. 2024(01): 127-129 .
2.	高成强，毕司星，李立新. CT平扫联合增强扫描在胰腺癌诊断中的应用价值. 影像研究与医学应用. 2024(02): 31-33 .
3.	侯胜楠. CT、MRI增强扫描对胰腺癌与慢性胰腺炎的鉴别诊断价值. 中华养生保健. 2024(07): 176-180 .
4.	柳群力，朱鸷翔. CT联合分泌型卷曲受体蛋白4及可溶性生长刺激表达基因2蛋白对恶性胆道梗阻患者术后并发胰腺炎的诊断价值. 实用临床医药杂志. 2024(05): 59-62+67 . 本站查看
5.	郑北. 联合应用CT、MRI增强扫描鉴别诊断胰腺癌与慢性胰腺炎的价值. 中国医疗器械信息. 2024(08): 12-14+25 .
6.	曹中立. 多层螺旋CT在胰腺癌术前评估及诊断中的应用价值. 影像研究与医学应用. 2024(10): 132-134 .
7.	杨懿，黄新蓉. MRI与CT检查诊断急性胰腺炎的价值比较研究. 影像研究与医学应用. 2024(14): 135-137+140 .
8.	董源涛，尚金红，袁燕丽. MRI联合CT在胰腺肿瘤中的诊断价值. 影像研究与医学应用. 2024(16): 137-139 .
9.	游红莲，闫明艳，褚千琨，王芳芳，陈文晶，于根建，王静. 隐匿性小胰腺癌并急性胰腺炎与单纯性急性胰腺炎的CT对比分析. 临床误诊误治. 2024(17): 63-68 .
10.	刘强. 多层螺旋CT与MRI扫描鉴别诊断胰腺癌和胰腺炎的有效性探讨. 影像研究与医学应用. 2024(19): 24-26 .

Other cited types(1)

Get Citation

PDF

XML

Article views (441) PDF downloads (28) Cited by(11)

Turn off MathJax

Article Contents

Abstract

References

Establishment of the model for selection of dominant advanced triple negative breast cancer patients with chemotherapy under the guidance of individualized gene detection